Atlas Trials

Phase I Study to Assess the Safety, Tolerability, and Pharmacokinetics of Orally Administered CUDC-101 in Cancer Patients

Clinical trial NCT01702285 · TERMINATED

Trial details

NCT number
NCT01702285
Sponsor
Curis, Inc.
Status
TERMINATED
Phase
Phase 1
Study type
INTERVENTIONAL
Cancer
Start date
2012-09-01
Primary completion
2012-12-01
Enrollment
3

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.